Study of an experimental drug or combination of drugs to treat castration resistant metastatic prostate cancer

What we are studying

The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone,and enzalutamide with enzalutamide alone on you and your prostate cancer to find out which is better. In this study, you will get either the combination of abiraterone, prednisone, and enzalutamide or enzalutamide alone. Abiraterone and enzalutamide are both hormonal agents approved by the Food and Drug Administration for patients with castration-resistant metastatic disease. Each drug works in a different way to block hormones.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 90

Eligibility Criteria

  • Subjects must be able to swallow pills

What is involved

  • Study participants in Arm A will take enzalutamide in 28-day cycles as long as their cancer is responding to treatment
  • Study participants in Arm B will take enzalutamide with or without abiraterone and prednisone in 28-day cycles as long as their cancer is responding to treatment



Contact Information

Study Coordinator
Patricia Smith

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.